Autoimmune Skin Diseases and Immune Checkpoint Inhibitors

被引：0

作者：

Fattore, Davide ^{[1
,3
]}

Potestio, Luca ^{[1
]}

Genco, Lucia ^{[1
]}

Pages, Cecile ^{[2
]}

Ortiz, Ariadna ^{[2
]}

Fabbrocini, Gabriella ^{[1
]}

Sibaud, Vincent ^{[2
]}

机构：

[1] Univ Naples Federico II, Dept Clin Med & Surg, Sect Dermatol, Naples, Italy

[2] Canc Univ Inst, Toulouse Oncopole, Dept Oncodermatol, Toulouse, France

[3] Univ Naples Federico II, Dept Clin Med & Surg, Sect Dermatol, Via Pansini 5, I-80131 Naples, Italy

来源：

CRITICAL REVIEWS IN IMMUNOLOGY | 2022年 / 42卷 / 03期

关键词：

immune checkpoint inhibitors; immune-related adverse events; autoimmune disease; lupus erythematosus; vitiligo; dermatomyositis; morphea; scleroderma; vasculitis; alopecia areata; alopecia universalis; ALOPECIA-AREATA; VITILIGO; NIVOLUMAB; DERMATOMYOSITIS; THERAPY;

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Immune system escape is one of the major strategies required for cancer growths. In this scenario, the advent of immune checkpoint inhibitors (ICIs) revolutionized the landscape of treatment options for tumors. Despite their wide use, these agents are associated with a unique spectrum of toxicities known as immune-related adverse events (irAEs). IrAEs are cause of treatment suspension (up to 60% of all causes of treatment interruption) and potentially impact on patients' quality of life. These toxicities are the main limitations on the use of these innovative drugs. IrAEs are peculiar, due to the mechanism of actions of ICIs, and any body organs may be involved (skin, thyroid, colon, lungs, in particular). Thus, the management often requires a multidisciplinary approach. The aim of this manuscript is to review current literature on autoimmune skin diseases described in association with ICIs (i.e., vitiligo, lupus erythematosus, vasculitis, morphea/scleroderma, alopecia areata, bullous pemphigoid, dermatomyositis), in order to provide a comprehensive overview for the physician.

引用

页码：11 / 22

页数：12

共 78 条

[1] BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors [J].